| Literature DB >> 22536500 |
M Scharin1, T Archer, P Hellström.
Abstract
Background. Several studies have found that patients with affective-/anxiety-/stress-related syndromes present overlapping features such as cooccurrence within families and individuals and response to the same type of pharmacological treatment, suggesting that these syndromes share pathogenetic mechanisms. The term affective spectrum disorder (AfSD) has been suggested, emphasizing these commonalities. The expectancy rate, sociodemographic characteristics, and global level of functioning in AfSD has hitherto not been studied neglected. Material and Method. Out of 180 consecutive patients 94 were included after clinical investigations and ICD-10 diagnostics. Further investigations included well-known self-evaluation instruments assessing psychiatric symptoms, personality disorders, psychosocial stress, adaptation, quality of life, and global level of functioning. A neuropsychological screening was also included. Results. The patients were young, had many young children, were well educated, and had about expected (normal distribution of) intelligence. Sixty-one percent were identified as belonging to the group of AfSD. Conclusion. The study identifies a large group of patients that presents much suffering and failure of functioning. This group is shared between the levels of medical care, between primary care and psychiatry. The term AfSD facilitates identification of patient groups that share common traits and identifies individuals clinically, besides the referred patients, in need of psychiatric interventions.Entities:
Year: 2012 PMID: 22536500 PMCID: PMC3320004 DOI: 10.1155/2012/527827
Source DB: PubMed Journal: Depress Res Treat ISSN: 2090-1321
Schematic model of Affective spectrum disorders (AfSDs), an interpretation and expansion of the concept as discussed in [2–6, 8].
| Dysphoria | Anxiety | Impulse | Stress |
|---|---|---|---|
| Major depression* | Generalized anxiety* | ADHD* | PTSD* |
| Dysthymic disorder* | Social phobia* | Bulimia nervosa* | Burnout syndromes (fatigue syndrome)*** |
| Bipolar disorder I** | Panic disorder* | “Binge-and-purge” eating disorder* | |
| Bipolar disorder II** | OCD* | Borderline personality disorder*** | |
| Anancastic and avoidant personality disorder*** | |||
| Bodily complaints | |||
| Fibromyalgia, irritable bowel syndrome, cataplexy, migraine* | |||
*Hudson and Pope [2–6], **[8], ***authors' inference.
Figure 1Flow chart depicting extraction of the 94 eligible patients observed in the study.
Sociodemographic description of the included patients (n = 94). All numbers are percentages.
| Gender | Children | ||
|---|---|---|---|
| Male/female | 37/63 | Yes/no | 65/35 |
| Age | Education | ||
|
| |||
| 18–29 | 28 | Unfinished primary school | 5 |
| 30–39 | 31 | Primary school (=9 years) | 19 |
| 40–49 | 18 | Secondary or vocational school | 47 |
| 50–59 | 11 | University | 26 |
| ≥60 | 12 | No information | 3 |
|
| |||
| Accommodations | Income | ||
|
| |||
| Apartment | 51 | Salary/student loan | 38 |
| Villa/house | 26 | Sickness benefit | 32 |
| Tenant | 10 | Pension | 12 |
| No information | 13 | Social/unemployment benefit | 9 |
| Other | 5 | ||
| No information | 4 | ||
|
| |||
| Marital status | Decent | ||
|
| |||
| Married/stable living arrangements | 45 | Born in Sweden, no foreign decent | 73 |
| Single | 28 | Born in Sweden, foreign decent | 8 |
| Divorced/living apart from partner | 20 | Foreign-born, Europe | 9 |
| Widow/widower | 3 | Foreign-born, the orient | 9 |
| No information | 4 | Foreign-born, other | 1 |
Previous treatment and ongoing medication (n = 94). Numbers are percentages.
| Previous treatment | Current medication | ||
|---|---|---|---|
| None specified previous contact | 23 | Any medication | 75 |
| Physician | 52 | SSRIs | 42 |
| Psychologist | 33 | Tranquilizer | 13 |
| Physiotherapist | 15 | Sleep medicine | 12 |
| Counselor | 17 | Pain medicine | 9 |
| Nurse | 5 | Antipsychotic medication | 5 |
| Occupational Therapist | 6 | ||
| Other | 8 |
SSRI: selective serotonin reuptake inhibitor.
Quality of life according to SF 36 (n = 91).
| Quality of life SF 36 | Md (range) |
|---|---|
| Physical function (PF) | 85 (0–100) |
| Role physical (RP) | 25 (0–100) |
| Bodily pain (BP) | 41 (0–100) |
| General health (GH) | 42 (5–97) |
| Vitality (VT) | 25 (0–80) |
| Social function (SF) | 38 (0–100) |
| Role emotional (RE) | 0 (0–100) |
| Mental health (MH) | 32 (0–92) |
The severity of stress generated by stressful life events (axis 4, DSM-IV).
| Severity of stress | |
|---|---|
|
|
|
| Severe | 33 |
| Moderate | 27 |
| Extreme | 22 |
| None/light | 8 |
| Catastrophic | 6 |